Stratum Nutrition, the specialist in eggshell and eggshell membrane wellness ingredients, has released findings of its clinical trial. The study was an independent muticentre operation that looked at effects on those with arthritic conditions.
President of Stratum, Micah Osborne, explained that the trial was a large, double-blind, placebo-controlled trial in Turkey to evaluate the efficacy of the company’s flagship ingredient, NEM. The study looked at NEM brand eggshell membrane in 166 subjects diagnosed with Grade 2 or Grade 3 osteoarthritis of the knee.
NEM contains naturally-occurring glycosaminoglycans, such as chondroitin and hyaluronic acid, as well as three varieties of collagen.
The study investigated the ingredient’s effect on pain and stiffness after seven, 30, 60, then 90 days. Conducted at eight different university medical centres in Turkey the trial supported NEM’s results after only 7 days and By Day 30, both knee pain and stiffness had improved by more than 30%.
This study also employed a unique blinded, single-crossover design to compare subjects taking NEM for 90 days versus subjects taking NEM for 60 days (former placebo subjects who began taking NEM after Day 30). The analysis found a statistically significant difference between the number of patients having at least a 15% decrease in pain, which was greater in the 90-day group.
“This is the largest study conducted to date involving NEM and we are pleased that it was supportive of its fast time to efficacy, even in subjects with moderate to severe arthritis,” said Kevin Ruff, Senior Director of Scientific & Regulatory Affairs for Stratum Nutrition. “This, combined with its cartilage protecting effects recently demonstrated in healthy individuals, makes NEM the perfect adjunctive therapy for those with joint issues.”
